ROTHBLATT MARTINE A sold $5.2M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $548.96 ($546.93–$553.90, $5.22M total) across 8 trades on 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may monitor for follow-on insider activity, but the disclosure alone does not change the company’s fundamentals or near-term catalysts.
Market read
A single insider sale of ~$5.2M at ~$547–$554/share, filed the next day, is more of a sentiment datapoint than a fundamental catalyst.
What to watch
The article doesn’t state whether other insiders sold/bought around the same time, nor does it provide context on total planned volume or remaining 10b5-1 schedule.
Background
This is an SEC Form 4 insider transaction by the company’s Chairperson & CEO, reported as an open-market sale under a Rule 10b5-1 plan.
Ticker impact
United Therapeutics CEO/Chair sold $5.2M of UTHR in an open-market transaction under a pre-arranged 10b5-1 plan on 2026-07-06.
Likely limited near-term price impact; any effect is more sentiment/positioning than fundamentals.
The filing discloses transaction size, price range, and 10b5-1 pre-arrangement, but provides no new operational, regulatory, or guidance information.
Market effects
No direct sector read-through; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a bearish view.
Key entities
- issuerUNITED THERAPEUTICS Corp
Subject of the Form 4 insider sale; CEO/Chair sold shares totaling ~$5.2M.
- insiderROTHBLATT MARTINE A
Chairperson & CEO who executed the open-market sales under a 10b5-1 plan.
